

PII: S0040-4020(96)00304-3

A New Pathway to Substituted 6-Chloro-2-pyridinecarboxylic Acid Derivatives from the Reaction of 4,6-Dichloro-2-oxa-5-azabicyclo[2.2.2]oct-5-en-3-ones with Nucleophiles.

Kristof J. Dubois and Georges J. Hoornaert*

Laboratorium voor Organische Synthese, Department of Chemistry, K. U. Leuven, Celestijnenlaan 200 F, B-3001 Heverlee, Belgium.

Dedicated to Professor Miha Tišler on the occasion of his 70th Birthday.

Abstract: Reaction of alcohols or amines with 4,6-dichloro-2-oxa-5-azabicyclo[2.2.2]oct-5-en-3-ones gives direct conversion into (3,(4,))5-substituted 6-chloro-2-pyridinecarboxylic acid derivatives via selective lactone cleavage followed by rapid elimination of HCl and H₂O in the presence of DBU. Copyright © 1996 Elsevier Science Ltd

Methods for the generation of multisubstituted 6-chloro-2-pyridinecarboxylic acid derivatives are not always obvious and often of a narrow scope.¹ However they can be important precursors as many 6-substituted 2-pyridinecarboxylic acid derivatives are known to be useful compounds as pharmaceutics or as agrochemicals.² Recently we reported a general method for the generation of variably substituted 1,6-dihydro-6-oxo-2-pyridine-(and piperidine-) carboxylic acid derivatives by using (\pm) -4,6-dichloro-2-oxa-5-azabicyclo[2.2.2]oct-5-en-3-ones 1 and 3.³ Here we describe an adapted route for the generation of 6-chloro-2-pyridinecarboxylic acid derivatives applying the reaction of the cycloadducts 1 and 3 with alcohols or amines in the presence of DBU.

RESULTS AND DISCUSSION.

The 5-substituted 6-chloro-2-pyridinecarboxylic acid derivatives 2 were obtained from an one pot procedure by using the easily accessible Diels-Alder adducts 1^4 of 6-substituted 3,5-dichloro-2*H*-1,4-oxazin-2ones⁵ and ethene (Scheme 1). Addition of 1.1 equivalent of ethanol at room temperature to a stirred reaction mixture of adduct 1a and 3 equivalents of DBU in CHCl₃ (or THF) gave a new product that was isolated after 15 minutes reaction in 83 % yield. It was characterised as the ethyl 6-chloro-5-methyl-2-pyridinecarboxylate 2a with an IR absorption for the ester group around 1720 cm⁻¹. The mass spectrum of 2a with relative abundance of M^+ , $[M+2]^+$ ions (3:1) pointed to the presence of one chlorine atom. In the ¹H NMR spectrum of 2a two typical doublets were observed (7.43 ppm and 7.95 ppm) which could attributed to the pyridine protons in the 3 and 4 position; ¹³C NMR absorptions were consistent with the assigned structure. Formation of a 1,6-dihydro-6-oxo-2-pyridinecarboxylate, as observed³ when reacting 1a with alcohols in neutral or acidic conditions followed by treatment of DBU, did not occur. Apparently a fast, selective attack of the alcohol (1.1 equivalents) on the lactone function took place followed by rapid elimination of HCl and H_2O (under influence of DBU that serves as a base) without affecting the chlorimine function. As expected, similar reaction of 1a with methanol and of 1b with ethanol gave a good yield of the 2-pyridinecarboxylates 2b and 2c, respectively after 30 minutes reaction at room temperature (Scheme 1). The 6-chloro-2-pyridinecarboxamide 2d (80 %) and 2e (68 %) could be isolated after 30 minutes reaction of 1a with propylamine or piperidine in the presence of DBU.



Scheme 1: Synthesis of 5-substituted 6-chloro-2-pyridinecarboxylic acid derivatives 2.

Futhermore the method could also be applied to the crude cycloadducts⁴ of the 3,5-dichloro-6-methyl-2H-1,4-oxazin-2-one and mono- or disubstituted alkene compounds (such as styrene, ethyl vinyl ether, allyl phenyl ether, cyclopentene and 4,7-dihydro-1,3-dioxepin) (Scheme 2). In a typical experiment the 3,5-dichloro-6-methyl-2H-1,4-oxazin-2-one⁵ was reacted with 3 equivalents of dienophile in refluxing CHCl₃. After completion of the cycloaddition and evaporation of the solvent, 3 equivalents of DBU were added to the unpurified adduct in CHCl₃.⁶ After five minutes of stirring at room temperature ethanol or propylamine (1.1 eq. or 3 eq.) was added slowly. Moderate yields (38 - 61 %) of the 3(,4),5-substituted 6-chloropyridines 4a-e were isolated along with a low amount (9 - 26 %) of products of type 5 in some cases. Probably, functionalisation of the chlorimine function competes with lactone cleavage due to the sterical hindrance of the substituent in the (7 and) 8 position of the adduct. The mass spectra of compounds 4 showed M⁺, [M+2]⁺ peaks with relative abundance 3:1 indicating the presence of one chlorine atom. In the ¹H NMR spectra of 4a-c a singlet was observed (7.25 ppm - 8.02 ppm) which could be attributed to the pyridine proton in the 4 position. Absorptions corresponding to two ethyl groups (5a) or propyl groups (5d) were observed in the ¹H NMR spectra of 5a,d showing functionalisation of the chlorimine function by ethanol or propylamine. Cycloadducts with electron withdrawing groups in the (7 and) 8 position (e.g. COOEt or CONPhCO⁴) gave tarry products on reaction with ethanol and DBU (or Et₃N) and the expected pyridine derivatives could not be observed.



Scheme 2: Synthesis of 3(,4),5-substituted 6-chloro-2-pyridinecarboxylic acid derivatives 4.

^a Crude adduct from the reaction of 3,5-dichloro-6-methyl-2H-1,4-oxazin-2-one and the corresponding dienophile has been used.

^b Yield calculated from the amount of crude adduct 3.

^c Only traces, if any, of the 6-ethoxy or 6-propylamino-pyridine were observed.

In conclusion we can state that the unsubstituted bicyclic adducts 1 and the (7,)8-substituted adducts 3 can be efficiently transformed into (3,(4,))5-substituted 6-chloro-2-pyridinecarboxylic acid derivatives 2 and 4 by an easy one pot procedure using alcohols or amines in the presence of DBU. The desired substitution pattern of the 6-chloro-2-pyridinecarboxylic acid derivative can be realised by choosing the appropriate cycloadduct and nucleophile. However electron withdrawing groups could not be introduced directly into the 3 and 4 position. This problem can be overcome by deprotection and subsequent oxidation of the alcohol function(s) in the pyridine 4c or in the [1,3]dioxepino[5,6-c]pyridine 4e. If required, further functionalisation of the 6-chloropyridine moiety would be possible.⁷

EXPERIMENTAL SECTION

Infrared spectra were recorded on a Perkin-Elmer 297 grating IR spectrophotometer and a Perkin-Elmer 1720 Fourier transform spectrometer. ¹H NMR spectra and ¹³C NMR spectra were recorded on a Bruker WM 250 or on a Bruker AMX 400 instrument. The ¹H and ¹³C chemical shifts are reported in ppm relative to TMS or the deuterated solvent as an internal reference. Mass spectra were run by using a Kratos MS50TC instrument and a DS90 data system. For the chromatography analytical TLC plates (Alugram Sil G/UV₂₅₄) and 70-230 mesh silica gel 60 (E.M. Merck) were used. Melting points were taken using a Reichert-Jung Thermovar apparatus and an Electrothermal IA 9000 digital melting point apparatus and are uncorrected. Microanalyses were performed by Janssen Pharmaceutica on a Carlo Erba elemental analyser type 1106. Synthesis and spectroscopic data of all the mentioned cycloadducts except 3c and 3e are described in a previous article.⁴

I. General procedure for the 5-substituted 6-chloro-2-pyridinecarboxylates and -carboxamides 2a-e.

A mixture of adduct 1a or 1b (5 mmol) in CHCl₃ (10 ml) and DBU (15 mmol) was stirred for 5 min at r.t.. On addition of the alcohol or amine (5.5 mmol) an exothermic reaction took place and after 15 - 30 min the solvent was removed under reduced pressure. Chromatography on silica gel with CH₂Cl₂/EtOAc (8:2) as eluent afforded compounds 2a-e (yield: 68-83 %, Table 1). Analytical samples were obtained by recrystallisation in *n*-Hex/CH₂Cl₂ (2b,c) or by bulb to bulb distillation (2a,d,e).

Ethyl 6-chloro-5-methyl-2-pyridinecarboxylate 2a.

oil, bp: 135 °C, 2 mm Hg; IR (NaCl plates) cm⁻¹: 1720 (s), 1563 (m); ¹H NMR (CDCl₃) δ : 1.42 (t, 3H, J = 7 Hz, CH₂CH₃), 2.45 (s, 3H, 5-CH₃), 4.45 (q, 2H, J = 7 Hz, CH₂CH₃), 7.43 (dq, 1H, J = 7.5 Hz, 1 Hz, H-4), 7.95 (d, 1H, J = 7.5 Hz, H-3); ¹³C NMR (CDCl₃): 13.9 (CH₃), 19.5 (5-CH₃), 61.5 (CH₂), 123.4 (C-3), 136.5 (C-5), 139.6 (C-4), 145.6 (C-2), 151.5 (C-6), 163.5 (CO); m/z (%): 199 (M⁺, 7), 155 (26), 127 (100); exact mass calcd for C₉H₁₀ClNO₂: 199.0400; found: 199.0401; anal cald for C₉H₁₀ClNO₂: C 54.15, H 5.05, N 7.02; found: C 54.35, H 4.91, N 6.79

Methyl 6-chloro-5-methyl-2-pyridinecarboxylate 2b.

m.p.: 77 °C (*n*-Hex/CH₂Cl₂); IR (KBr) cm⁻¹: 1736 (s), 1560 (m); ¹H NMR (CDCl₃) δ : 2.47 (s, 3H, 5-CH₃), 3.98 (s, 3H, CH₃), 7.73 (d, 1H, J = 7.5 Hz, H-4), 8.07 (d, 1H, J = 7.5 Hz, H-3); ¹³C NMR (CDCl₃): 19.8 (5-CH₃), 52.8 (CH₃), 123.8 (C-3), 137.1 (C-5), 139.8 (C-4), 145.6 (C-2), 151.6 (C-6), 164.6 (CO); m/z (%): 185 (M⁺, 10), 155 (20), 127 (100); exact mass calcd for C₈H₈ClNO₂: 185.0244; found: 185.0247; anal cald for C₈H₈ClNO₂: C 51.77, H 4.34, N 7.55; found: C 51.87, H 4.06, N 7.46

Ethyl 6-chloro-5-phenyl-2-pyridinecarboxylate 2c.

m.p.: 85 °C (*n*-Hex/CH₂Cl₂); IR (KBr) cm⁻¹: 1720 (s); ¹H NMR (CDCl₃) δ : 1.53 (t, 3H, J = 7 Hz, CH₂CH₃), 4.59 (q, 2H, J = 7 Hz, CH₂CH₃), 7.55 (s, 5H, H_{arom}), 7.88 (d, 1H, J = 7.5 Hz, H-4), 8.17 (d, 1H, J = 7.5 Hz, H-3); ¹³C NMR (CDCl₃): 14.1 (CH₃), 62.0 (CH₂), 123.7 (C-3), 128.3, 128.6, 129.0 (C_{arom}), 136.7 (C_{ipao}), 140.2 (C-4), 140.4 (C-5), 146.9 (C-2), 149.6 (C-6), 163.8 (CO); m/z (%): 261 (M⁺, 24), 217 (11), 189 (100), 153 (30); exact mass calcd for C₁₄H₁₂CINO₂: 261.0556; found: 261.0558; anal cald for C₁₄H₁₂CINO₂: C 64.25, H 4.62, N 5.35; found: C 64.25, H 4.44, N 5.30

N-**Propyl-6-chloro-5-methyl-2-pyridinecarboxamide 2d.**

oil, bp: 145 °C, 2 mm Hg; IR (NaCl plates) cm⁻¹: 1680 (s), 1527 (s); ¹H NMR (CDCl₃) δ : 1.01 (t, 3H, J = 7 Hz, N(CH₂)₂CH₃), 1.70 (sext, 2H, J = 7 Hz, NHCH₂CH₂CH₃), 2.42 (s, 3H, 5-CH₃), 3.43 (q, 2H, J = 7 Hz, NCH₂CH₂CH₂CH₃), 7.69 (d, J = 7.5 Hz, 1H, H-4), 7.88 (br s, 1H, NH), 8.02 (d, J = 7.5 Hz, 1H, H-3); ¹³C NMR (CDCl₃): 11.1 (CH₃), 19.4 (5-CH₃), 22.6 (CH₂), 40.9 (NCH₂), 120.7 (C-3), 135.2 (C-5), 140.1 (C-4), 147.9 (C-2), 149.6 (C-6), 162.7 (CO); m/z (%): 212 (M⁺, 31), 183 (72), 154 (100), 126 (80); exact mass calcd for C₁₀H₁₃ClN₂O: 212.0716; found: 212.0715; anal cald for C₁₀H₁₃ClN₂O: C 56.47, H 6.16, N 13.17; found: C 56.22, H 6.12, N 12.96

N-Piperidinyl-6-chloro-5-methyl-2-pyridinecarboxamide 2e.

oil, bp: 145 °C, 2 mm Hg; IR (NaCl plates) cm⁻¹: 1640 (s), 1550 (m); ¹H NMR (CDCl₃) δ : 1.25 (m, 2H, (CH₂)₂CH₂(CH₂)₂), 1.68 (m, 4H, CH₂CH₂NCH₂CH₂), 2.41 (s, 3H, 5-CH₃), 3.47 en 3.70 (m, 4H, CH₂NCH₂), 7.45 (d, 1H, J = 8 Hz, H-4), 7.66 (d, 1H, J = 8 Hz, H-3); ¹³C NMR (CDCl₃): 19.3 (5-CH₃), 24.1, 25.1, 26.0 (CH₂), 43.0, 47.9 (CH₂NCH₂), 121.8 (C-3), 133.1 (C-5), 139.8 (C-4), 149.6 (C-2), 151.8 (C-6), 165.6 (CO); m/z (%): 238 (M⁺, 8), 154 (10), 126 (22), 84 (1000); exact mass calcd for C₁₂H₁₅ClN₂O: 238.0873; found: 238.0874; anal cald for C₁₂H₁₅ClN₂O: C 60.38, H 6.33, N 11.74; found: C 60.07, H 6.30, N 11.53

II. Synthesis and spectroscopic data of cycloadducts 3c and 3e.

Allyl phenyl ether or 4,7-dihydro-1,3-dioxepin (0.017 mmol, 3 equiv) was added at once to a stirred solution of 3,5-dichloro-6-methyl-2H-1,4-oxazin-2-one³ (1.0 g, 5.6 mmol) in CHCl₃ (5 ml). After reflux for 6 hours the solvent was evaporated and the crude reaction mixture purified by chromatography (silica gel, eluent: 5 % EtOAc/CHCl₃) 3c (60 %, for the other regioisomer see ref 3) or by crystallisation by adding 2 ml of diisopropyl ether 3e (82 %).

(±)-Endo 4,6-dichloro-1-methyl-8-phenoxymethyl-2-oxa-5-azabicyclo[2.2.2]oct-5-en-3-one 3c.

m.p.: 105 °C (CCl₄); IR (KBr) cm⁻¹: 1780 (s), 1610 (s); ¹H NMR (CDCl₃) δ : 1.75 (s, 3H, 1-CH₃), 1.90 - 3.00 (m, 3H, H-7endo, H-7exo, H-8exo), 3.95 and 4.41 (m, 2H, CH₂O), 6.91 - 7.32 (m, 5H, Ar-H); ¹³C NMR (CDCl₃): 20.4 (1-CH₃), 36.0, 42.4 (C-7 and C-8), 66.4 (CH₂O), 83.0 (C-4), 86.8 (C-1), 114.8, 121.8, 129.8 (Ar-C), 158.0 (C-ipso), 163.6 (C-6), 164.6 (C-3); $J_{C6-CH_3} = 5$ Hz, $J_{C6-H7exo} = 9$ Hz, $J_{C6-H7endo} \approx 1$ Hz, $J_{C3-H7exo} = 9$ Hz, $J_{C6-H7endo} \approx 1$ Hz, $J_{C3-H7exo} = 9$ Hz, $J_{C6-H7endo} \approx 1$ Hz, $J_{C3-H7exo} = 9$ Hz, $J_{C6-H7exo} = 9$ Hz, $J_{C6-H7exo} = 9$ Hz, $J_{C6-H7exo} \approx 1$ Hz, $J_{C3-H7exo} \approx 1$ Hz, $J_{$

 $H_{Bexo} = 2.5$ Hz, indicative for an 8-substituted *endo* structure^{4,8}; m/z (%): 313 (M⁺, 11), 236 (10), 107 (32), 94 (100); exact mass calcd for C₁₄H₁₃N₁O₃Cl₂: 313.0271; found 313.0268

(±)-Endo 4,6-dichloro-1-methyl-2,10,12-trioxa-5-azatricyclo[7.2.2.0^{7,8}]tridec-5-en-3-one 3e.

m.p.: 178 °C (CH₂Cl₂/Diisopropyl ether); IR (KBr) cm⁻¹: 1613 (s), 1785 (s); ¹H NMR (CDCl₃) δ : 1.82 (s, 3H, 1-CH₃), 2.67 (m, 2H, H-7exo, H-8exo), 3.83 and 4.29 (2 x br. s, 4H, (CH₂O)₂), 4.91 (br. d, 2H, OCH₂O); ¹³C NMR (CDCl₃): 18.5 (1-CH₃), 47.7, 50.5 (C-7 and C-8), 64.4 and 68.9 (2 x CH₂O), 84.8 (C-4), 87.2 (C-1), 99.2 (OCH₂O), 163.0 (C-6), 164.8 (C-3); $J_{C6-CH_3} = 5$ Hz, $J_{C6-H_7exo} = 7$ Hz, $J_{C3-H_8exo} \approx 1$ Hz, indicative for an 7,8-disubstituted endo structure^{4,8}; m/z (%): 280 (MH⁺, 1), 235 (1), 205 (4), 170 (35), 140 (44), 44 (100); exact mass calcd for C₁₀H₁₀N₁O₄Cl₂ [M⁺-H]: 277.9986; found : 277.9994

III. General procedure for the synthesis of 3(,4-di)substituted 6-chloro-5-methyl-2-pyridinecarboxylates or - carboxamides 4 and the corresponding 6-ethoxy or 6-propylamino derivatives 5.

A stirred solution of 3,5-dichloro-6-methyl-2H-1,4-oxazin-2-one⁵ (1 g, 5.5 mmol) and dienophile (16.5 mmol) in CHCl₃ (5 ml) is refluxed for 30 min - 6 h. Disappearance of the typical dark violet color (due to the 3,5-dichloro-6-methyl-2H-1,4-oxazin-2-one) under UV light (366 nm) on TLC (silica gel, CH₂Cl₂/EtOAc (8:2)) was indicative for completion of the reaction.⁶ Evaporation of the solvent and dienophile gave the crude adducts which were dissolved in CHCl₃ (5 ml), DBU (16.5 mmol) was added and the mixture was stirred for 5 min at r.t.. To this solution EtOH (0.35 ml, 6.1 mmol, **3a-c**) or propylamine (0.50 ml, 18.3 mmol, **3d,e**) was added dropwise and the mixture stirred for 1 h at r.t. (**3a-c**) (reflux, **3d,e**). After removal of the solvent under reduced pressure, chromatography on silica gel with CH₂Cl₂/EtOAc (8:2) as eluent afforded **4a-e** and **5a,d** as pure compounds (Table 2). Analytical samples were obtained by recrystallisation.

Ethyl 6-chloro-5-methyl-3-phenyl-2-pyridinecarboxylate 4a.

m.p.: 90 °C (*n*-Hex/CH₂Cl₂); IR (KBr) cm⁻¹: 1736 (s), 1540 (w); ¹H NMR (CDCl₃) δ : 1.10 (t, 3H, J = 7 Hz, CH₂CH₃), 2.43 (s, 3H, 5-CH₃), 4.20 (q, 2H, J = 7 Hz, CH₂CH₃), 7.32 (m, 5H, H_{aron}), 7.59 (s, 1H, H-4); ¹³C NMR (CDCl₃): 13.6 (CH₃), 19.5 (5-CH₃), 61.6 (CH₂), 128.2, 128.3, 128.4 (C_{aron}), 134.6 (C-5), 136.2 (C-3), 137.1 (C_{ipso}), 141.4 (C-4), 146.3 (C-2), 149.8 (C-6), 165.6 (CO); m/z (%): 275 (M⁺, 18), 230 (13), 203 (100), 168 (28); exact mass calcd for C₁₅H₁₄ClNO₂: 275.0713; found: 275.0710; anal cald for C₁₅H₁₄ClNO₂: C 65.34, H 5.12, N 5.08; found: C 64.99, H 5.00, N 4.99

Ethyl 6-chloro-3-ethoxy-5-methyl-2-pyridinecarboxylate 4b.

mp: 82 °C (*n*-Hex/CH₂Cl₂); IR (KBr) cm⁻¹: 1719 (s), 1588 (w); ¹H NMR (CDCl₃) δ : 1.45 (m, 6H, 2 x CH₂CH₃), 2.40 (s, 3H, 5-CH₃), 4.12 (q, 2H, J = 7 Hz, CH₂CH₃), 4.44 (q, 2H, J = 7 Hz, CH₂CH₃), 7.25 (s, 1H, H-4); ¹³C NMR (CDCl₃): 14.1, 14.5 (CH₃), 20.0 (5-CH₃), 61.5, 65.3 (CH₂), 124.6 (C-4), 136.5 (C-2), 136.6 (C-5), 141.3 (C-6), 153.8 (C-3), 163.9 (CO); m/z (%): 243 (M⁺, 23), 214 (67), 198 (35), 143 (100); exact mass calcd for C₁₁H₁₄ClNO₃: 243.0662; found: 243.0662; anal cald for C₁₁H₁₄ClNO₃: C 54.22, H 5.79, N 5.75; found: C 54.36, H 5.79, N 5.72

Ethyl 6-chloro-5-methyl-3-phenoxymethyl-2-pyridinecarboxylate 4c.

mp: 113 °C (*n*-Hex/CH₂Cl₂); IR (KBr) cm⁻¹: 1706 (s), 1596 (m), 1545 (w); ¹H NMR (CDCl₃) δ : 1.39 (t, 3H, J = 7 Hz, CH₂CH₃), 2.45 (s, 3H, 5-CH₃), 4.44 (q, 2H, J = 7 Hz, CH₂CH₃), 5.43 (s, 2H, CH₂OPh), 7.00 and 7.30 (m, 5H, H_{arom}), 8.02 (s, 1H, H-4); ¹³C NMR (CDCl₃): 14.2 (CH₃), 19.8 (5-CH₃), 62.1 (CH₂), 65.9 (OCH₂Ph), 114.7, 121.4, 129.6 (C_{arom}), 135.1 (C-3), 136.5 (C-5), 138.9 (C-4), 142.4 (C-2), 149.8 (C-6), 158.1 (C_{ipeo}), 164.8 (CO); m/z (%): 305 (M⁺, 20), 259 (11), 212 (18), 184 (100); exact mass calcd for C₁₆H₁₆ClNO₃: 305.0819; found: 305.0816; anal cald for C₁₆H₁₆ClNO₃: C 62.85, H 5.27, N 4.58; found: C 62.95, H 5.07, N 4.55

N-Propyl-6,7-dihydro-3-chloro-4-methyl-5H-2-pyridine-1-carboxamide 4d.

mp: 120 °C (Et₂O/Diisopropyl ether); IR (KBr) cm⁻¹: 1655 (s), 1523 (s); ¹H NMR (CDCl₃) δ : 1.00 (t, 3H, J = 7 Hz, CH₂CH₂CH₃), 1.65 (sext, 2H, J = 7 Hz, CH₂CH₂CH₃), 2.16 (pent, 2H, J = 7 Hz, CH₂CH₂CH₂), 2.34 (s, 3H, 4-CH₃), 2.88 (t, 2H, J = 7 Hz, CH₂CH₂CH₂), 3.41 (m, 4H, CH₂CH₂CH₂ and NHCH₂CH₂CH₂CH₃), 7.90 (br s, 1H, NH); ¹³C NMR (CDCl₃): 11.4 (CH₃), 16.4 (4-CH₃), 22.9, 24.7, 31.7, 32.2 (CH₂), 40.8 (NCH₂), 130.9 (C-4), 140.4 (C-7a), 141.8 (C-1), 147.2 (C-3), 158.6 (C-4a), 164.4 (CO); m/z (%): 252 (M⁺, 76), 223 (51), 195 (16), 167 (100); exact mass calcd for C₁₃H₁₇ClN₂O: 252.1029; found: 252.1032; anal cald for C₁₃H₁₇ClN₂O: C 61.78, H 6.78, N 11.08; found: C 61.80, H 6.93, N 11.10

N-Propyl-1,5-dihydro-8-chloro-9-methyl-[1,3]dioxepino[5,6-c]pyridine-6-carboxamide 4e.

mp: 145 °C (CH₂Cl₂/Diisopropyl ether); IR (KBr) cm⁻¹: 1639 (s), 1542 (s); ¹H NMR (CDCl₃) δ : 0.99 (t, 3H, J = 7 Hz, NHCH₂CH₂CH₂CH₃), 1.62 (sext, 2H, J = 7 Hz, NHCH₂CH₂CH₃), 2.33 (s, 3H, 9-CH₃), 3.35 (q, 2H, J = 7 Hz, NHCH₂CH₂CH₂CH₃), 4.90 (s, 2H, CH₂O), 4.95 (s, 2H, CH₂O), 5.41 (s, 2H, OCH₂O), 7.82 (br s, 1H, NH); ¹³C NMR (CDCl₃): 11.4 (CH₃), 15.5 (9-CH₃), 22.8 (CH₂), 41.1 (NCH₂), 66.7, 67.3 (CH₂O), 96.6 (OCH₂O), 131.0 (C-9), 136.2 (C-5a), 144.2 (C-6), 148.1 (C-8), 152.3 (C-9a), 164.4 (CO); m/z (%): 284 (M⁺, 6), 254 (9), 226 (7), 197 (8), 169 (23), 141 (21), 58 (100); exact mass calcd for C₁₃H₁₇ClN₂O₃: 284.0928; found: 284.0929; anal cald for C₁₃H₁₇ClN₂O₃: C 54.84, H 6.02, N 9.84; found: C 54.96, H 6.03, N 9.82

Ethyl 6-ethoxy-5-methyl-3-phenyl-2-pyridinecarboxylate 5a.

oil; IR (NaCl plates) cm⁻¹: 1736 (s), 1606 (m); ¹H NMR (CDCl₃) δ : 0.90 (t, 3H, J = 7 Hz, CH₂CH₃), 1.32 (t, 3H, J = 7 Hz, CH₂CH₃), 2.15 (s, 3H, 5-CH₃), 4.03 (q, 2H, J = 7 Hz, CH₂CH₃), 4.38 (q, 2H, J = 7 Hz, CH₂CH₃), 7.25 (m, 5H, H_{arom}), 7.35 (s, 1H, H-4); ¹³C NMR (CDCl₃): 13.5, 14.5 (CH₃), 15.7 (5-CH₃), 60.9, 61.9 (CH₂), 123.1 (C-5), 127.1, 128.0, 128.2 (C_{arom}), 130.1 (C-3), 138.7 (C_{ipso}), 140.4 (C-4), 142.9 (C-2), 160.7 (C-6), 167.2 (CO); m/z (%): 285 (M⁺, 100), 270 (60), 257 (51); exact mass calcd for C₁₇H₁₉NO₃: 285.1365; found: 285.1366

N-Propyl-6,7-dihydro-3-propylamino-4-methyl-5H-2-pyridine-1-carboxamide 5d.

mp: 158 °C (CH₂Cl₂/Diisopropyl ether); IR (KBr) cm⁻¹: 3357 (m), 1657 (s), 1606 (m); ¹H NMR (CDCl₃) δ : 1.00 (m, 6H, 2 x NHCH₂CH₂CH₃), 1.65 (m, 4H, 2 x NHCH₂CH₂CH₃), 2.04 (pent, 2H, J = 7.5 Hz, CH₂CH₂CH₂), 2.05 (s, 3H, 4-CH₃), 2.76 (t, 2H, J = 7.5 Hz, CH₂CH₂CH₂), 3.32 (t, 2H, J = 7.5 Hz, CH₂CH₂CH₂), 3.40 (m, 4H, 2 x -NHCH₂CH₂CH₃), 4.15 (br s, 1H, NH), 8.16 (br s, 1H, CONH); ¹³C NMR (CDCl₃): 11.4, 11.7 (2 x NHCH₂CH₂CH₃), 13.2 (4-CH₃), 22.8, 23.0 (2 x NHCH₂CH₂CH₃), 25.1 (CH₂CH₂CH₂), 31.0, 31.8 (CH₂CH₂CH₂), 40.5, 43.9 (2 x NHCH₂CH₂CH₂), 115.6 (C-4), 130.5 (C-7a), 138.7 (C-1), 153.9 (C-4a), 154.9 (C-3), 166.4 (CO); m/z (%): 275 (M⁺, 76), 190(100), 159 (73); exact mass calcd for C₁₆H₂₅N₃O₁: 275.1997; found: 275.1996

Acknowledgements. The authors are indebted to the F.K.K.O. and the "Ministerie voor Wetenschapsbeleid-I.U.A.P - 16" for financial support. K.D. wishes to thank the I.W.O.N.L. and I.W.T. for a fellowship. The authors are also grateful to Dr. F. Compernolle, Dr. S. Toppet, and R. De Boer for technical assistance and the Janssen Pharmaceutica Company for elemental analyses.

REFERENCES

- Ogino, H.; Iwamatsu, K.; Katano, K.; Nakabayashi, S.; Yoshida, T.; Tsuruoka, T.; Inouye, S.; Kondo, S. J. Antibiotics 1990, 43, 2, 174-188; Rao, K.V.; Venkateswarlu, P. J. Heterocycl. Chem. 1975, 731-735; Blank, B.; Ditullio, N.W.; Miao, C.K.; Owings, F.F.; Gleason, J.G.; Ross, S.T.; Berkoff, C.E.; Saunders, H.L. J. Med. Chem. 1974, 17, 10, 1065-1071; Kiener, A. Angew. Chem. 1992, 104, 748-749.
- See, for recent examples: Makino, E.; Iwasaki, N.; Yagi, N.; Ohashi, T.; Kato, H.; Ito, Y.; Azuma, H. Chem. Pharm. Bull. 1990, 38, 201-207. Foster, C.J.; Gilkerson, T.; Stocker, R. European Patent # 447,004 (Chem. Abstr. 1992, 116, 128668e). Finkelstein, B.L., US Patent # 794,554 (Chem. Abstr. 1993, 119, 160130w). Takasugi, H.; Kuno, A.; Sakai, H. European Patent # 387,070 (Chem. Abstr. 1991, 114, P101743x). Takabe, F.; Saito, Y.; Tamaru, M.; Tachikawa, S.; Yoshida, R. Japanese Patent # 06,316,574 (Chem. Abstr. 1995, 122, 160668e). Kleemann, A.; Graef, H. British Patent # 2,277,930 (Chem. Abstr. 1995, 122, 105924).
- 3. Dubois, K.; Fannes, C.; Compernolle, F.; Hoornaert, G. Tetrahedron 1996, in press.
- 4. Fannes, C.; Meerpoel, L.; Hoornaert, G. Synthesis, 1992, 705-709.
- 5. Meerpoel, L.; Hoornaert, G. Synthesis 1990, 905-908.
- 6. Cycloadducts 3 (except 3c, e) and their yields have been described in ref 4.
- Kiener, A.; Glöckler, R.; Heinzmann, K. J. Chem. Soc. Perkin Trans 1 1993, 1201-1202. Yamamoto, Y.; Azuma, Y.; Mitoh, H. Synthesis 1986, 564-565. Yamamoto, Y.; Yamagi, A. Chem. Pharm. Bull. 1982, 30, 1731-1737; Yamamoto, Y.; Yamagi, A. Chem. Pharm. Bull. 1982, 30, 2003-2010; Kutsher, B.; Dieter, H.R.; Trömer, H.-G.; Bartz, B.; Engel, J.; Kleeman, A. Liebigs Ann. 1995, 591-592; Trécourt, F.; Mallet, M.; Mongin, O.; Quéguiner, G. J. Org. Chem. 1994, 59, 6173-6178.
- Kalinowski, H.; Berger, S.; Braun, S. In Carbon-13 NMR Spectroscopy, John Wiley and Sons: New York, 1988; p 526.

(Received in UK 9 February 1996; accepted 21 March 1996)